LAT CAB (2021-present)
The LAT CAB is a new cross-disease long-acting technologies (LAT) community advisory board focused on malaria, the hepatitis C virus, and latent TB infection.
Materials in this section
About
LAT CAB reviews the state of treatment research, contributes to research protocols, and engages in the research and development process for long-acting technologies for malaria, HCV, and LTBI. More
Communities as Actors in the Research and Development Process
A publication, released by Treatment Action Group, explores the role of community engagement in health-related research and development, particularly within the Unitaid-funded LONGEVITY Project. More
Preferences of Patients and Providers in High-Burden Malaria Settings for Long-Acting Malaria Chemoprevention
A survey of Kenyan and Zambian patient end-users, prescribers, and policymakers evaluates the acceptance of and potential concerns about long-acting formulations of malaria chemoprevention. More
Long-Acting Therapies Trials Tracker for Hepatitis C, Opioid Use and Overdose Prevention Therapy, and Malaria
Treatment Action Group releases a trials tracker providing a compilation of ongoing clinical trials on long-acting treatments for HCV, malaria, and opioid use and overdose prevention. More
Prospects for Long-Acting Treatments for Hepatitis C
Long-acting parenteral formulations of HCV treatment may allow people living with hepatitis C virus infection to be diagnosed and cured in a single encounter. More
Community Call to Action on Equitable Access to Long-Acting Therapies
The growing pipeline for LAT and their potential to accelerate various disease elimination goals warrants global community mobilization to ensure equitable access to these therapies. More
LAT CAB Brochure
Learn about LAT CAB, Longevity project and meet the LAT CAB community experts. More
Community Mobilization to Ensure Health Systems’ Readiness for Long-Acting Therapies - Webinar Recording Now Available Online
Webinar organized by Treatment Action Group, INPUD and AfroCAB. More
The LAT CAB Responds to MedinCell and Medicines Patent Pool License on a New Long-Acting Malaria Formulation
Every minute a child in Sub-Saharan Africa dies from malaria; these are preventable deaths! More
MPP and MedinCell Sign Licence Agreement for mdc-STM, an Investigational Long-Acting Injectable Formulation to Fight Malaria Transmission
The non-exclusive licence agreement will enable MPP to support the identification of suitable partners for the development and commercialisation of mdc-STM. More
